The invention belongs to the technical field of medical examination, and particularly relates to application of detection reagents of eight
metabolic markers in preparation of
breast cancer diagnosis and prognosis products. The
metabolic markers are
heptanal, 2-
pentanone, 2, 2-dimethyl-propionic acid, 2-decyl decahydronaphthalene, 3, 4, 5, 6, 7, 8-hexahydro-2 (1H)-naphthalenone, 2-[(2-cyano-3, 3-dimethyl cyclopropyl) methyl]-2-methyl-1, 3-dioxolame, methyl
isopropyl disulfide and dimethyl
silane glycol, and the PubChem CID is 8130, 7895, 6417, 586218, 572673, 560018, 123494 and 11137539 in sequence; research results show that compared with normal healthy people, the combined diagnosis index of the eight
metabolic markers in the
urine of the
breast cancer patient is increased, the eight metabolic markers can be used as the
urine marker for predicting the incidence of the
breast cancer, the combined evaluation
curative effect index of the eight metabolic markers is increased
after treatment, and the breast
cancer treatment effect can be evaluated. The result provides a specific, rapid and noninvasive detection means for early diagnosis,
dynamic monitoring and prognosis of breast
cancer, and has wide clinical application value.